Home

Zenas BioPharma, Inc. - Common Stock (ZBIO)

8.0300
-0.0300 (-0.37%)

Zenas Biopharma Inc is a biotechnology company focused on developing innovative therapies for patients with rare diseases and unmet medical needs

The company leverages advanced research and scientific expertise to create targeted treatments aimed at improving health outcomes. With a commitment to addressing complex medical challenges, Zenas Biopharma strives to enhance the quality of life for individuals living with debilitating conditions through its cutting-edge drug development programs and collaborations within the biopharmaceutical industry.

SummaryNewsPress ReleasesChartHistoricalFAQ
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progressbenzinga.com
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.
Via Benzinga · March 20, 2025
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 22, 2025
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · December 16, 2024
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · December 11, 2024
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · October 25, 2024
StandardAero Surges In Market Debuttalkmarkets.com
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at $22.
Via Talk Markets · October 6, 2024
Week In Review: Zenas Raises $259 Million In IPOtalkmarkets.com
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259 million to complete development of its product.
Via Talk Markets · September 28, 2024
Trio Of Biotech IPOs Climb In Debuttalkmarkets.com
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public offerings than they had planned.
Via Talk Markets · September 15, 2024